ABBV · 8-K · 20260903PR104940

Product / Drug Pipeline Progress

AbbVie Inc. · 2026-09-03 · Importance 30 · Surprise 42

Apogee adds late-stage and early-stage antibody programs targeting atopic dermatitis, asthma and other inflammatory diseases to AbbVie's immunology pipeline. Zumilokibart, an IL-13 antibody in development for atopic dermatitis, produced clinically significant Phase 2 results, with approximately two-thirds of treated patients achieving significant skin clearance at 16 weeks and longer-term data supporting quarterly or twice-yearly dosing. APG273 combines zumilokibart with APG333, a TSLP-blocking antibody; Phase 1 data showed APG333 suppressed relevant type 2 inflammatory markers for up to six months, while Phase 1b asthma results supported potential quarterly or twice-yearly injections.

Key facts

• APG273 combines zumilokibart with APG333, an antibody that blocks thymic stromal lymphopoietin (TSLP). source
• Apogee's lead asset, zumilokibart, is a late-stage, half-life extended monoclonal antibody targeting IL-13 in development for patients with atopic dermatitis. source
• Longer-term data from the same trial support maintenance regimens of either quarterly or twice a year dosing for zumilokibart. source
• Apogee's pipeline includes APG273, a potential long-acting combination targeting IL-13 and thymic stromal lymphopoietin (TSLP), in development for asthma. source
• Phase 1b interim results of zumilokibart in asthma were positive, supporting the potential of the APG273 combination with quarterly or twice-yearly injections in asthma. source
• In its Phase 2 clinical trial, zumilokibart attained clinically significant results with approximately two-thirds of patients on treatment achieving significant skin clearance at 16 weeks. source
• Phase 1 data showed that APG333 has a long half-life and was able to suppress relevant type 2 inflammatory markers for up to six months after dosing. source
• Apogee's pipeline targets large immunology and inflammation markets including atopic dermatitis (AD), asthma, and chronic obstructive pulmonary disease (COPD). source